Ultrasound monitoring of hidradenitis suppurativa fistulas in treatment with adalimumab

Recently, ultrasound has become a significant tool in studying hidradenitis suppurativa (HS), allowing differentiation between abscesses and fistulas, and assessing various disease features. However, there is still a lack of data on using ultrasound (US) to assess treatment response to medical trea...

Full description

Saved in:
Bibliographic Details
Main Authors: Raffaele Dante Caposiena Caro, Giulia Bazzacco, Enrico Zelin, Vanessa Mazzoletti, Nicola Di Meo, Iris Zalaudek
Format: Article
Language:English
Published: PAGEPress Publications 2025-04-01
Series:Dermatology Reports
Subjects:
Online Access:https://www.pagepress.org/journals/dr/article/view/10124
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849769645395935232
author Raffaele Dante Caposiena Caro
Giulia Bazzacco
Enrico Zelin
Vanessa Mazzoletti
Nicola Di Meo
Iris Zalaudek
author_facet Raffaele Dante Caposiena Caro
Giulia Bazzacco
Enrico Zelin
Vanessa Mazzoletti
Nicola Di Meo
Iris Zalaudek
author_sort Raffaele Dante Caposiena Caro
collection DOAJ
description Recently, ultrasound has become a significant tool in studying hidradenitis suppurativa (HS), allowing differentiation between abscesses and fistulas, and assessing various disease features. However, there is still a lack of data on using ultrasound (US) to assess treatment response to medical treatment. The study aims to assess the clinical usefulness of ultrasound in monitoring disease activity in HS patients undergoing treatment with adalimumab over a 52-week period. This research employs a retrospective approach to analyze ultrasound scores related to fibrosis, edema, power-Doppler (PD) signal, and resistive index (RI) at baseline and after 52 weeks of adalimumab treatment. In total, 311 fistulas from 69 patients were included. Multivariate regression analysis showed that PD score and edema were related to IHS4-55 and variations of DLQI and pain-VAS. Furthermore, at baseline, healed and non-healed fistulas were characterized by significant differences in PD signal, fibrosis, edema, and RI. Limitations include the retrospective design of the study, a limited population size, and the absence of a control group. However, our data provide evidence that ultrasound can be a reliable tool for assessing patients’ responses to medical therapies.
format Article
id doaj-art-5123ad71abdc4b7cb68d24a16dc72299
institution DOAJ
issn 2036-7392
2036-7406
language English
publishDate 2025-04-01
publisher PAGEPress Publications
record_format Article
series Dermatology Reports
spelling doaj-art-5123ad71abdc4b7cb68d24a16dc722992025-08-20T03:03:21ZengPAGEPress PublicationsDermatology Reports2036-73922036-74062025-04-0110.4081/dr.2025.10124Ultrasound monitoring of hidradenitis suppurativa fistulas in treatment with adalimumabRaffaele Dante Caposiena Caro0Giulia Bazzacco1Enrico Zelin2Vanessa Mazzoletti3Nicola Di Meo4Iris Zalaudek5Dermatology Clinic, Hospital Maggiore of Trieste, University of TriesteInstitute of Dermatology, Santa Maria della Misericordia University Hospital, UdineInstitute of Dermatology, Santa Maria della Misericordia University Hospital, UdineInstitute of Dermatology, Santa Maria della Misericordia University Hospital, UdineDermatology Clinic, Hospital Maggiore of Trieste, University of TriesteDermatology Clinic, Hospital Maggiore of Trieste, University of Trieste Recently, ultrasound has become a significant tool in studying hidradenitis suppurativa (HS), allowing differentiation between abscesses and fistulas, and assessing various disease features. However, there is still a lack of data on using ultrasound (US) to assess treatment response to medical treatment. The study aims to assess the clinical usefulness of ultrasound in monitoring disease activity in HS patients undergoing treatment with adalimumab over a 52-week period. This research employs a retrospective approach to analyze ultrasound scores related to fibrosis, edema, power-Doppler (PD) signal, and resistive index (RI) at baseline and after 52 weeks of adalimumab treatment. In total, 311 fistulas from 69 patients were included. Multivariate regression analysis showed that PD score and edema were related to IHS4-55 and variations of DLQI and pain-VAS. Furthermore, at baseline, healed and non-healed fistulas were characterized by significant differences in PD signal, fibrosis, edema, and RI. Limitations include the retrospective design of the study, a limited population size, and the absence of a control group. However, our data provide evidence that ultrasound can be a reliable tool for assessing patients’ responses to medical therapies. https://www.pagepress.org/journals/dr/article/view/10124Hidradenitis suppurativaultrasoundadalimumab
spellingShingle Raffaele Dante Caposiena Caro
Giulia Bazzacco
Enrico Zelin
Vanessa Mazzoletti
Nicola Di Meo
Iris Zalaudek
Ultrasound monitoring of hidradenitis suppurativa fistulas in treatment with adalimumab
Dermatology Reports
Hidradenitis suppurativa
ultrasound
adalimumab
title Ultrasound monitoring of hidradenitis suppurativa fistulas in treatment with adalimumab
title_full Ultrasound monitoring of hidradenitis suppurativa fistulas in treatment with adalimumab
title_fullStr Ultrasound monitoring of hidradenitis suppurativa fistulas in treatment with adalimumab
title_full_unstemmed Ultrasound monitoring of hidradenitis suppurativa fistulas in treatment with adalimumab
title_short Ultrasound monitoring of hidradenitis suppurativa fistulas in treatment with adalimumab
title_sort ultrasound monitoring of hidradenitis suppurativa fistulas in treatment with adalimumab
topic Hidradenitis suppurativa
ultrasound
adalimumab
url https://www.pagepress.org/journals/dr/article/view/10124
work_keys_str_mv AT raffaeledantecaposienacaro ultrasoundmonitoringofhidradenitissuppurativafistulasintreatmentwithadalimumab
AT giuliabazzacco ultrasoundmonitoringofhidradenitissuppurativafistulasintreatmentwithadalimumab
AT enricozelin ultrasoundmonitoringofhidradenitissuppurativafistulasintreatmentwithadalimumab
AT vanessamazzoletti ultrasoundmonitoringofhidradenitissuppurativafistulasintreatmentwithadalimumab
AT nicoladimeo ultrasoundmonitoringofhidradenitissuppurativafistulasintreatmentwithadalimumab
AT iriszalaudek ultrasoundmonitoringofhidradenitissuppurativafistulasintreatmentwithadalimumab